Charcot-Marie Muscular Atrophy

Charcot-Marie muscular atrophy (CHMA, English Charcôt-Marie's myasthenia gravis, French myasthénie gravis des deux deuxièmes du nom de Charcôt and French Marie-Charcot-Barbier) is a systemic autoimmune disease that develops against the background of atonic and thymomegaly. This is a chronic and recurrent disease, which is accompanied by weakening of muscle tissue of all types, disruption of the sensory organs and muscle paresis, which increases gradually, from

Charcot-Marzin muscular atrophy is a hereditary neurodegenerative disease that manifests itself in progressive muscle weakness, muscle atrophy, paralysis and impaired motor coordination. This disease is caused by a mutation in the gene that encodes the protein alpha-synuclein, which leads to disruption of signal transmission from neurons to muscle cells.

The first scientific study of Charcot Marcionis muscle was carried out in 1966 by a team of French neurologists. In their experiments, they studied the characteristics of symptoms in family members who suffered from this disease. They found that in the genetic structure of carriers